LAG3 and plasma cell myeloma: Another phase I/II randomized trial tested the efficacy of anti-TIGIT and anti-LAG3 mAbs in patients with relapsed refractory multiple myeloma either alone or in combination with pomalidomide and dexamethasone (NCT04150965, NCT02913313).